Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Charles Weissmann's ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The partnership between Biogen ...

Join RAPS Boston for an in-person Executive Chat with Diane Rocco, SVP of Global Regulatory Affairs at Biogen, moderated by Ami Mehr. The discussion will explore how regulatory leadership shapes key ...

Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug ...

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist. Biogen described C5aR1 as a ...

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen. The biopharma has paid $50 ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Biogen said Tuesday that ...